Quarterly report [Sections 13 or 15(d)]

Strategic Agreements - Additional Information (Details)

v3.25.1
Strategic Agreements - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2018
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Derivative liabilities - royalty agreement   $ 1,722   $ 1,647
Ligand Development Funding Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Payments totalling to fund development $ 15,000      
Maximum payments to receive upon achievement of milestones $ 8,000      
Agreement royalty term period from first sale 15 years      
Agreement termination notice period 90 days      
Aggregate potential future milestone payments remaining under arrangement   5,000    
Derivative liabilities - royalty agreement   $ 1,700   $ 1,600
Effective interest rate percentage of potential future royalty payments   39.90%   39.90%
Non-cash interest expense   $ 1,200 $ 800  
Ligand Development Funding Agreement [Member] | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty percentage 9.80%      
Ligand Development Funding Agreement [Member] | Minimum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty percentage 8.00%